Literature DB >> 26769457

Trophic factors for Parkinson's disease: To live or let die.

C Warren Olanow1, Raymond T Bartus2, Laura A Volpicelli-Daley3, Jeffrey H Kordower4.   

Abstract

Trophic factors show great promise in laboratory studies as potential therapies for PD. However, multiple double-blind, clinical trials have failed to show benefits in comparison to a placebo control. This article will review the scientific rationale for testing trophic factors in PD, the results of the different clinical trials that have been performed to date, and the possible explanations for these failed outcomes. We will also consider future directions and the likelihood that trophic factors will become a viable therapy for patients with PD.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Trophic Factors; Parkinson's Disease; GDNF; Neurturin

Mesh:

Substances:

Year:  2015        PMID: 26769457     DOI: 10.1002/mds.26426

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

Review 1.  Neurotoxins as Preclinical Models for Parkinson's Disease.

Authors:  Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2018-01-08       Impact factor: 3.911

2.  Do subjects with minimal motor features have prodromal Parkinson disease?

Authors:  Yaping Chu; Aron S Buchman; C Warren Olanow; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2018-03-10       Impact factor: 10.422

Review 3.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

Review 4.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Authors:  Yvette C Wong; Kelvin Luk; Kerry Purtell; Samuel Burke Nanni; A Jon Stoessl; Louis-Eric Trudeau; Zhenyu Yue; Dimitri Krainc; Wolfgang Oertel; Jose A Obeso; Laura A Volpicelli-Daley
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

Review 5.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

Review 6.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

7.  On the Role of DT-Diaphorase Inhibition in Aminochrome-Induced Neurotoxicity In Vivo.

Authors:  Andrea Herrera-Soto; Gabriela Díaz-Veliz; Sergio Mora; Patricia Muñoz; Pablo Henny; Harry W M Steinbusch; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2017-03-11       Impact factor: 3.911

8.  Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson's Disease.

Authors:  Amirah E-E Aly; Brendan T Harmon; Linas Padegimas; Ozge Sesenoglu-Laird; Mark J Cooper; Barbara L Waszczak
Journal:  Mol Neurobiol       Date:  2018-05-19       Impact factor: 5.590

9.  Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease.

Authors:  Andrea Herrera; Patricia Muñoz; Irmgard Paris; Gabriela Díaz-Veliz; Sergio Mora; Jose Inzunza; Kjell Hultenby; Cesar Cardenas; Fabián Jaña; Rita Raisman-Vozari; Katia Gysling; Jorge Abarca; Harry W M Steinbusch; Juan Segura-Aguilar
Journal:  Cell Mol Life Sci       Date:  2016-03-21       Impact factor: 9.261

Review 10.  Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?

Authors:  Jia-Yi Li; Wen Li
Journal:  Front Cell Dev Biol       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.